Inspire(US:INSP) Businesswireยท2025-11-14 17:06Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. (INSP) for securities fraud, following a significant drop in stock price due to poor performance and misleading statements regarding the launch of its new sleep apnea device, Inspire V [1][3][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of shareholders who purchased Inspire common stock between August 6, 2024, and August 4, 2025, with a deadline for filing a lead plaintiff motion set for January 5, 2026 [1]. - The lawsuit alleges that the company made materially false and misleading statements and failed to disclose adverse facts about its business and operations during the class period [5]. Group 2: Company Performance - On August 4, 2025, Inspire disclosed that the launch of the Inspire V device was facing delays due to issues such as incomplete training for treatment centers, software update delays, and excess inventory leading to poor demand [3]. - The company reduced its 2025 earnings guidance by over 80%, from a range of $2.20 to $2.30 per share down to $0.40 to $0.50 per share [3]. Group 3: Stock Impact - Following the announcement of these issues, Inspire's stock price fell by $42.04, or 32.4%, closing at $87.91 per share on August 5, 2025, resulting in significant losses for investors [4].